Mini device implanted during surgery could reveal pancreatic Cancer's weakness
NCT ID NCT07254091
First seen Dec 08, 2025 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This early-phase study tests a small implantable device that delivers tiny amounts of different cancer drugs directly into a pancreatic tumor during surgery. After about 4 hours, the device is removed with the tumor, and researchers check which drugs killed the most cancer cells. The goal is to see if this approach is safe and can help choose the right treatment for each patient. Only 10 people having pancreatic surgery will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zuckerberg Cancer Center
RECRUITINGNew Hyde Park, New York, 11040, United States
Conditions
Explore the condition pages connected to this study.